<i>In vitro</i>, <i>in vivo</i> and <i>ex vivo</i> characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter <scp>MRP1</scp>

Abstract

Our results indicated that ibrutinib significantly increased the efficacy of the chemotherapeutic agents which were MRP1 substrates, in MRP1-overexpressing cells, in vitro, in vivo and ex vivo. These findings will lead to further studies on the effects of a combination of ibrutinib with chemotherapeutic agents in cancer patients overexpressing MRP1.